KSE - Delayed Quote KRW

JW Lifescience Corporation (234080.KS)

12,350.00 +80.00 (+0.65%)
At close: 3:30 PM GMT+9
Loading Chart for 234080.KS
DELL
  • Previous Close 12,270.00
  • Open 12,270.00
  • Bid --
  • Ask --
  • Day's Range 12,220.00 - 12,370.00
  • 52 Week Range 11,670.00 - 15,160.00
  • Volume 8,259
  • Avg. Volume 18,305
  • Market Cap (intraday) 191.235B
  • Beta (5Y Monthly) 0.56
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield 500.00 (4.07%)
  • Ex-Dividend Date Dec 27, 2023
  • 1y Target Est 18,000.00

JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.

www.jw-lifescience.co.kr

--

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: 234080.KS

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

234080.KS
4.04%
KOSPI Composite Index
0.04%

1-Year Return

234080.KS
9.81%
KOSPI Composite Index
6.90%

3-Year Return

234080.KS
29.90%
KOSPI Composite Index
17.44%

5-Year Return

234080.KS
38.72%
KOSPI Composite Index
21.89%

Compare To: 234080.KS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 234080.KS

Valuation Measures

Annual
As of 4/25/2024
  • Market Cap

    190.00B

  • Enterprise Value

    207.96B

  • Trailing P/E

    6.75

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.92

  • Price/Book (mrq)

    1.19

  • Enterprise Value/Revenue

    1.01

  • Enterprise Value/EBITDA

    4.00

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.61%

  • Return on Assets (ttm)

    7.58%

  • Return on Equity (ttm)

    18.78%

  • Revenue (ttm)

    206.86B

  • Net Income Avi to Common (ttm)

    28.14B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.35B

  • Total Debt/Equity (mrq)

    29.06%

  • Levered Free Cash Flow (ttm)

    26.78B

Research Analysis: 234080.KS

Analyst Price Targets

18,000.00
18,000.00 Average
12,350.00 Current
18,000.00 High
 

Fair Value

 

Company Insights: 234080.KS

People Also Watch